FDA Grants Dasatinib Priority Review for Resistant CML

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Ziftomenib Earns FDA Priority Review for R/R NPM1-Mutant AML

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.

Roman Fabbricatore

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

American Society for Transplantation and Cellular Therapy

Rusfertide Combo Enhances Responses in Polycythemia Vera

Researchers conducted a prospective, multicenter phase II clinical trial demonstrating that prolonged administration of ruxolitinib after allogeneic HCT is associated with notably low rates of cGVHD.

Sabrina Serani

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

Related Content

Tim Cortese

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Ziftomenib Earns FDA Priority Review for R/R NPM1-Mutant AML

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Roman Fabbricatore

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

American Society for Transplantation and Cellular Therapy

Rusfertide Combo Enhances Responses in Polycythemia Vera

Researchers conducted a prospective, multicenter phase II clinical trial demonstrating that prolonged administration of ruxolitinib after allogeneic HCT is associated with notably low rates of cGVHD.

Sabrina Serani